Dimensional Fund Advisors LP Has $107.08 Million Position in Masimo Co. (NASDAQ:MASI)

Dimensional Fund Advisors LP lifted its position in shares of Masimo Co. (NASDAQ:MASI) by 8.4% during the 4th quarter, Holdings Channel reports. The firm owned 647,720 shares of the medical equipment provider’s stock after purchasing an additional 50,022 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Masimo were worth $107,076,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC raised its stake in Masimo by 19.8% in the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock valued at $1,338,509,000 after buying an additional 1,340,836 shares during the period. Vanguard Group Inc. raised its stake in Masimo by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider’s stock valued at $758,182,000 after acquiring an additional 66,215 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock valued at $286,823,000 after purchasing an additional 943,001 shares during the last quarter. Alliancebernstein L.P. boosted its position in Masimo by 1,276.9% during the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after purchasing an additional 878,587 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Masimo by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 801,125 shares of the medical equipment provider’s stock valued at $132,465,000 after purchasing an additional 8,239 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the stock. Piper Sandler lifted their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Thursday, April 10th. Finally, Wells Fargo & Company increased their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Performance

Shares of NASDAQ:MASI opened at $163.74 on Monday. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company’s 50 day moving average price is $165.71 and its two-hundred day moving average price is $165.73. The firm has a market cap of $8.85 billion, a PE ratio of 112.92 and a beta of 1.28. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Equities research analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by company insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.